| Drug Type Gene therapy | 
| Synonyms MQ 710, MQ-710 | 
| Target | 
| Action modulators | 
| Mechanism Flt3L modulators(Fms-related tyrosine kinase 3 ligand modulators), OX40L modulators(Tumor necrosis factor ligand superfamily member 4 modulators), Gene transference(Gene transference) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePhase 1 | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Advanced cancer | Phase 1 | United States  | 04 May 2023 | |
| Basal Cell Carcinoma | Phase 1 | United States  | 04 May 2023 | |
| BRAF V600 mutation-positive Melanoma | Phase 1 | United States  | 04 May 2023 | |
| Cutaneous Squamous Cell Carcinoma | Phase 1 | United States  | 04 May 2023 | |
| Extramammary Paget Disease | Phase 1 | United States  | 04 May 2023 | |
| Hemangiosarcoma | Phase 1 | United States  | 04 May 2023 | |
| Kaposi Sarcoma | Phase 1 | United States  | 04 May 2023 | |
| Merkel Cell Carcinoma | Phase 1 | United States  | 04 May 2023 | |
| Neoplasm Metastasis | Phase 1 | United States  | 04 May 2023 | |
| Refractory Cancer | Phase 1 | United States  | 04 May 2023 | 





